FYR Bio

Executive Summary

FYR Bio is a San Diego-based biotechnology company pioneering an AI-powered multi-omic platform that analyzes extracellular vesicles (EVs) in blood to decode RNA and protein signals. This liquid biopsy approach aims to create dynamic biomarkers for precision medicine, improving clinical trial design and patient monitoring. Founded in 2020, the company operates in the diagnostics sector with a focus on non-invasive, real-time disease insights. While still in early stages (no disclosed funding or valuation), FYR Bio's technology leverages cutting-edge EV biology and machine learning, positioning it among innovative liquid biopsy players. The company's potential lies in enabling better patient stratification and treatment response tracking, addressing key inefficiencies in drug development and personalized care.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement65% success
• Q1 2027Peer-Reviewed Publication on EV Biomarker Platform50% success
• H2 2026Partnership with a Pharmaceutical Company for Clinical Trial Monitoring40% success